Inogen Inc (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 4,445 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $81.05, for a total value of $360,267.25. Following the completion of the sale, the director now directly owns 4,445 shares of the company’s stock, valued at approximately $360,267.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Inogen Inc (NASDAQ:INGN) traded down 0.14% on Monday, hitting $84.03. The stock had a trading volume of 191,728 shares. Inogen Inc has a 52 week low of $44.19 and a 52 week high of $88.61. The stock’s 50-day moving average price is $80.51 and its 200 day moving average price is $70.83. The company has a market cap of $1.73 billion, a PE ratio of 75.16 and a beta of 1.07.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, May 9th. The medical technology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.15. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The company had revenue of $52.50 million during the quarter, compared to analyst estimates of $49.06 million. During the same period in the previous year, the company earned $0.12 earnings per share. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. On average, analysts predict that Inogen Inc will post $1.04 EPS for the current year.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

ILLEGAL ACTIVITY WARNING: “Inogen Inc (INGN) Director Ray Benjamin M. Anderson Sells 4,445 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/22/inogen-inc-ingn-director-ray-benjamin-m-anderson-sells-4445-shares.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Investment Management LLC raised its position in shares of Inogen by 0.7% in the third quarter. BlackRock Investment Management LLC now owns 67,727 shares of the medical technology company’s stock worth $4,057,000 after buying an additional 449 shares during the period. Municipal Employees Retirement System of Michigan raised its position in shares of Inogen by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,220 shares of the medical technology company’s stock worth $193,000 after buying an additional 50 shares during the period. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Inogen during the third quarter worth approximately $211,000. State of Tennessee Treasury Department raised its position in shares of Inogen by 14.9% in the third quarter. State of Tennessee Treasury Department now owns 12,588 shares of the medical technology company’s stock worth $754,000 after buying an additional 1,630 shares during the period. Finally, Emerald Acquisition Ltd. raised its position in shares of Inogen by 287.4% in the third quarter. Emerald Acquisition Ltd. now owns 84,966 shares of the medical technology company’s stock worth $5,089,000 after buying an additional 63,031 shares during the period.

A number of equities research analysts have issued reports on the company. Needham & Company LLC upped their target price on Inogen from $78.00 to $83.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, March 1st. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 6th. JPMorgan Chase & Co. set a $78.00 target price on Inogen and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Stifel Nicolaus upped their target price on Inogen to $65.00 in a research report on Wednesday, March 1st. Finally, Sidoti assumed coverage on Inogen in a research report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 target price for the company. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $80.33.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

12 Month Chart for NASDAQ:INGN

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.